Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021057061 - SENOLYTIC AND ANTIINFLAMMATORY PRODRUGS AND METHODS OF USE THEREOF


Disclaimer The image version (PDF) available on PATENTSCOPE is the official version. This online html version is provided to assist users. Despite the great care taken in its compilation to ensure a precise and accurate representation of the data appearing on the printed document/images, errors and/or omissions cannot be excluded due to the data transmittal, conversion and inherent limitations of the (optional) machine translation processes used. Hyperlinks followed by this symbol , are to external resources that are not controlled by WIPO. WIPO disclaims all liability regarding the above points.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/CN2020/092933 IP200325
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
28 May 2020 25 September 2019
Applicant
PEKING UNIVERSITY
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1.
Claims Nos.: 19-29
because they relate to subject matter not required to be searched by this Authority, namely:
[1] Claims 19-29 direct to a method of selectively killing one or more senescent cells or ameliorating one or more symptoms associated with an inflammatory disorder in a subject, and do not meet the criteria set out in PCT Rules 39.1(iv). The search has been made and based on the use of the composition of claim 16 or 17 for the manufacturing of a medicament for the selectively killing one or more senescent cells or ameliorating one or more symptoms associated with an inflammatory disorder in a subject.
2.
Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3.
Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
3. Unity of invention is lacking
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     1B    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     C07H; A61K; A61P
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
CNABS;CNTXT;SIPOABS;DWPI;STNext:PEKING UNIVERSITY;DENG Hongkui;LUO Tuoping;CAI Yusheng;ZHOU Huanhuan;ZHU Yinhua;senescent;senescence;senolytic;inflammatory;cytotoxic;galactosidase; nitro;gemcitabine;cytarabine;fluorocytidine;prodrug;acetylate;95058-81-4 147-94-4;66335-38-4

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
WO 2017189553 A1 (EVERON BIOSCIENCES, INC.) 02 November 2017 (2017-11-02)
1-13,16-25,27-29
paragraphs 0039-0040,0057-0070,0127,0129,0156-0164,0178-0183,0216,0220-0221;example 23;Fig.15
(2)
X
US 5561119 A (LAB. HOECHST ET AL.) 01 October 1996 (1996-10-01)
1-13,16-18
claims 1-36
(3)
X
US 2018094015 A1 (WASHINGTON STATE UNIVERSITY) 05 April 2018 (2018-04-05)
1-13, 16-18
paragraphs 0002, 0068, 0086
(4)
X
WO 2009016647 A1 (COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH) 05 February 2009 (2009-02-05)
1-13,16-18
claims 1-3
(5)
X
GHOSH A. K. et al., "A daunorubicin b-galactoside prodrug for use in conjunction with gene-directed enzyme prodrug therapy.", Tetrahedron Letters.,Vol. 41, 31 December 2000 (2000-12-31),
1-13,16-18
pages 4871-4874
(6)
X
SHARMA A. et al., "Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation.", Biomaterials.,Vol. 155, 20 November 2017 (2017-11-20),
1-13,16-18
pages 145-151
(7)
X
KAMAL A. et al., "Development of PyrroloACHTUNGTRENUNG[2,1-c]ACHTUNGTRENUNG[1,4]benzodiazepine b-Galactoside Prodrugs for Selective Therapy of Cancer by ADEPT and PMT", ChemMedChem.,Vol. 3, 05 February 2008 (2008-02-05),
1-13,16-18
pages 794-802
(8)
X
HANTHO J.D. et al., "An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.", ChemMedChem Communications.,Vol. 11, 11 October 2016 (2016-10-11),
1-13,16-18
pages 2496-2500
(9)
X
SCHUSTER H.J. et al., "Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity.", Organic & Biomolecular Chemistry.,Vol. 8, 17 February 2010 (2010-02-17),
1-13,16-18
pages 1833-1842
(10)
A
SARKAR A.K. et al., "Disaccharide uptake and priming in animal cells: Inhibition of sialyl Lewis X by acetylated Galβ1-4GlcNAcβ-O-naphthalenemethanol", Proc. Natl. Acad. Sci. USA.,Vol. 92, 30 April 1995 (1995-04-30),
1-29
pages 3323-3327
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
WO 2017189553 A1
02 November 2017
US 2020123127 A1
23 April 2020
US 5561119 A
01 October 1996
FR 2676058 B1
AU 1778892 A
CA 2109304 A1
KR 100254113 B1
JP H06506687 A
DE 69214712 D1
WO 9219639 A1
GR 3022344 T3
DK 0511917 T3
IE 921369 A1
CA 2109304 C
EP 0511917 B1
FR 2676058 A1
HK 1008020 A1
AT 144523 T
AU 673138 B2
ES 2096735 T3
JP 3053646 B2
DE 69214712 T2
EP 0511917 A1
25 February 1994
21 December 1992
31 October 1992
15 April 2000
28 July 1994
28 November 1996
12 November 1992
30 April 1997
01 April 1997
04 November 1992
15 January 2002
23 October 1996
06 November 1992
30 April 1999
15 November 1996
31 October 1996
16 March 1997
19 June 2000
07 May 1997
04 November 1992
US 2018094015 A1
05 April 2018
US 2020199166 A1
25 June 2020
WO 2009016647 A1
05 February 2009
JP 2010535195 A
AT 543826 T
EP 2188297 A1
JP 5404624 B2
US 7754694 B2
EP 2188297 B1
US 2009036657 A1
18 November 2010
15 February 2012
26 May 2010
05 February 2014
13 July 2010
01 February 2012
05 February 2009
Name and mailing address of the ISA/:
National Intellectual Property Administration, PRC
6, Xitucheng Rd., Jimen Bridge, Haidian District, Beijing 100088
China
Facsimile No. (86-10)62019451
Date of the actual completion of the international search:
14 August 2020
Date of mailing of the international search report:
03 September 2020
Authorized officer:
WU,Tiesheng
Telephone No. (86)10-53961870
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E